SOLESENCE, INC. SLSN revenue by segment, product and geography
In its fiscal year ending 2025-12-31, SOLESENCE, INC. reported revenue across 5 products and services; the largest, Product, was $61.8M (+19.1% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Product$61.8Mshare n/a+19.1% yoy
- Consumer Products$54.9Mshare n/a+23.7% yoy
- Personal Care Ingredients$6.34Mshare n/a-7.1% yoy
- Advanced Materials$857Kshare n/a-25.3% yoy
- Product And Service Other$270Kshare n/a-40.9% yoy
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Outside the United States$5.17M100.0%+183.2% yoy
Members sum to $5.17M against $62.1M consolidated (residual $56.9M) - eliminations or corporate lines the filer did not tag on this axis.
- Product$12.9Mshare n/a-11.4% yoy
- Consumer Products$10Mshare n/a-22.2% yoy
- Personal Care Ingredients$2.73Mshare n/a+98.5% yoy
- Advanced Materials$205Kshare n/a-44.6% yoy
- Product And Service Other$38Kshare n/a-24.0% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.